002880.SHE Shenzhen Weiguang Biological Products Co Ltd
- Market cap
- CNY 4.53B
- P/E
- 25.6x
- P/B
- 1.78x
- ROE
- 4.4%
- Dividend yield
- 1.45%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002880.SHE undervalued?
Graham number002880.SHE trades 42.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Weiguang Biological Products Co Ltd fundamental analysis
No fundamental analysis for Shenzhen Weiguang Biological Products Co Ltd yet.
Shenzhen Weiguang Biological Products Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenz…
Full company profileShenzhen Weiguang Biological Products Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Weiguang Biological Products Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 566M | 623M | 688M | 821M | 905M | 907M | 668M | 1.05B | 1.20B | 1.27B | 876M |
| Gross Profit | 268M | 276M | 274M | 315M | 336M | 371M | 241M | 433M | 504M | 499M | 318M |
| Operating Income | 169M | 179M | 182M | 199M | 221M | 242M | 138M | 247M | 297M | 324M | 153M |
| EBITDA | 238M | 232M | 228M | 239M | 266M | 299M | 204M | 347M | 435M | 458M | 155M |
| Net Income | 153M | 155M | 157M | 171M | 190M | 205M | 118M | 219M | 254M | 246M | 108M |
| EPS | 0.90 | 0.78 | 0.69 | 0.76 | 0.84 | 0.91 | 0.52 | 0.96 | 1.12 | 1.09 | 0.48 |
| Balance Sheet | |||||||||||
| Total Assets | 910M | 1.37B | 1.46B | 1.59B | 1.84B | 2.00B | 2.58B | 2.88B | 3.30B | 3.74B | 3.61B |
| Total Liabilities | 403M | 172M | 154M | 137M | 212M | 215M | 708M | 831M | 1.05B | 1.29B | 1.13B |
| Shareholders' Equity | 506M | 1.20B | 1.31B | 1.45B | 1.60B | 1.77B | 1.84B | 2.01B | 2.21B | 2.41B | 2.45B |
| Cash & Short-term Investments | 61.9M | 339M | 260M | 305M | 471M | 332M | 295M | 252M | 428M | 370M | 87.8M |
| Total Debt | 295M | 70.0M | 29.0M | - | 82.0M | 43.4M | 547M | 500M | 669M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 126M | 28.6M | 99.5M | 186M | 304M | 247M | 1.20M | 398M | 178M | 263M | - |
| Capital Expenditure | 59.9M | 61.4M | 84.5M | 77.8M | 189M | 241M | 327M | 329M | 256M | 170M | 104M |
| Free Cash Flow | 66.5M | -32.7M | 15.0M | 108M | 115M | 6.06M | -326M | 69.1M | -77.7M | 93.5M | -285M |
| Ratios | |||||||||||
| ROE | 30.3% | 12.9% | 12.0% | 11.8% | 11.9% | 11.6% | 6.4% | 10.9% | 11.5% | 10.2% | 4.4% |
| ROA | 16.8% | 11.3% | 10.7% | 10.8% | 10.4% | 10.3% | 4.6% | 7.6% | 7.7% | 6.6% | 3.0% |
| Net Profit Margin | 27.1% | 24.8% | 22.8% | 20.9% | 21.0% | 22.6% | 17.6% | 20.9% | 21.1% | 19.4% | 12.4% |
| Debt to Equity | 0.58x | 0.06x | 0.02x | - | 0.05x | 0.02x | 0.30x | 0.25x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Weiguang Biological Products Co Ltd dividends
- Dividend yield
- 1.45%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 26.7%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 65.7M | 0.29 | 26.7% |
| 2024 | CNY 65.9M | 0.29 | 26.0% |
| 2023 | CNY 65.6M | 0.29 | 30.0% |
| 2022 | CNY 45.4M | 0.20 | 38.6% |
| 2021 | CNY 40.5M | 0.18 | 19.7% |
| 2020 | CNY 35.7M | 0.16 | 18.7% |
| 2019 | CNY 32.5M | 0.14 | 19.0% |
| 2018 | CNY 57.3M | 0.25 | 36.6% |
| 2017 | CNY 94.0M | 0.47 | 60.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 16, 2021.
Who owns Shenzhen Weiguang Biological Products Co Ltd
- Insiders 76.06%
- Institutions 0.12%
- Public & others 23.82%
- Shares outstanding 227M
- Free float 56.5M
Shenzhen Weiguang Biological Products Co Ltd company profile
- Company name
- Shenzhen Weiguang Biological Products Co Ltd
- Ticker
- 002880.SHE
- ISIN
- CNE100002Q58
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 901
- Fiscal year end
- December
- Address
- No. 3402, Guangqiao Avenue, Shenzhen, China, 518107
- Phone
- 86 755 2740 0826
- Website
- szwg.com
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection freeze-dried, lyophilized human rabies vaccine and human prothrombin complex. Shenzhen Weiguang Biological Products Co., Ltd. was founded in 1985 and is based in Shenzhen, China.
Shenzhen Weiguang Biological Products Co Ltd management
5- Ms. Caiping GuoGM & Director · born 1971
- Mr. Guan Qun ChenCFO & Director · born 1977
- Mr. Wenjie XieDeputy GM & Employee Director · born 1976
- Ms. Xuefen LiuSecretary of the Board of Directors · born 1978
- Kui HuangAccounting Supervisor